BP control was achieved in 44% of obese and 56% BEZ235 of non-obese patients. Following re-randomization, non-obese patients experienced an increase in BP during placebo treatment, albeit levels remained below baseline, whereas BP reductions were maintained in valsartan recipients (P<.05). The most frequent adverse events during the open-label phase were headache and fever. Valsartan provides similar antihypertensive efficacy in obese and non-obese hypertensive children and adolescents, with good tolerability in both patient populations. J Clin Hypertens (Greenwich). 2011;13:758-766. (C) 2011 Wiley Periodicals, Inc.”
“The dispersion and stability of nanofluids obtained by dispersing Al2O3

nanoparticles (obtained from different sources) in water have been analyzed. The differences arising from different dispersion techniques, the resulting particle size distribution, and time stability among the different samples are evaluated. Then the volumetric behavior up to high pressures (25 MPa) and atmospheric pressure viscosity were experimentally determined. It has been found that the influence of particle size in density is subtle but not negligible, but the differences in viscosity are very large and must be taken into account for any practical application. These

viscosity differences can be rationalized by considering a theory describing the aggregation state of the nanofluid. (C) 2009 American Institute of Physics. [doi:10.1063/1.3187732]“
“ApneaLink is a novel single-channel screening PF-6463922 manufacturer device for sleep apnea detection which is based on pressure-transduced measurement GSK1120212 inhibitor of oronasal airflow, summarised as respiratory disturbance index per hour of recording time (RDI(ApneaLink)). We tested ApneaLink’s diagnostic performance in a patient population with high prevalence of sleep apnea.\n\nApneaLink was applied simultaneously with in-laboratory polysomnography (PSG) (n = 102, 24 female, age 54.7 years) and sequentially with PSG in the unattended

home setting (n = 131, 37 female, age 59.1 years). Predictive values were computed for apnea-defining thresholds of apnea-hypopnea index (AHI)>= 5/h, >= 10/h, >= 15/h. Night-to-night variability (NNV) was assessed over three consecutive nights (n = 55, 10 female, age 48.9 years).\n\nRDI(ApneaLink) correlated well with apnea-hypopnea index on PSG (PSG(AHI)) on simultaneous (r = 0.98, bias -0.7) and unattended home application (r = 0.95, bias -0.6). Predictive values were highest at AHI >= 10/h (in-laboratory: sensitivity 91.1%, specificity 87.5%, LR+ (positive likelihood ratio) 7.4, LR- 0.1; home: sensitivity 80%, specificity 85.5%, LR+5.5, LR- 0.2). NNV was low (V – 0.58 +/- 0.44, range 0 – 1.69).\n\nApneaLink is an accurate screening tool for sleep apnea in a population with high prevalence of the disorder.